Invesco Pharmaceuticals ETF $PJP Shares Newly Purchased by Trek Financial LLC

Trek Financial LLC acquired a new position in Invesco Pharmaceuticals ETF (NYSEARCA:PJP) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 46,386 shares of the company’s stock, valued at approximately $5,720,000. Trek Financial LLC owned 1.04% of Invesco Pharmaceuticals ETF at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Outlook Wealth Advisors LLC acquired a new stake in Invesco Pharmaceuticals ETF during the 3rd quarter valued at approximately $1,392,000. Partners Wealth Management LLC acquired a new position in shares of Invesco Pharmaceuticals ETF in the 3rd quarter worth approximately $299,000. North Star Investment Management Corp. acquired a new position in shares of Invesco Pharmaceuticals ETF in the 3rd quarter worth approximately $74,000. Latitude Advisors LLC acquired a new position in shares of Invesco Pharmaceuticals ETF in the 3rd quarter worth approximately $29,000. Finally, Valley National Advisers Inc. bought a new stake in shares of Invesco Pharmaceuticals ETF in the 3rd quarter valued at $163,000.

Invesco Pharmaceuticals ETF Stock Performance

NYSEARCA:PJP opened at $130.54 on Monday. Invesco Pharmaceuticals ETF has a 52 week low of $95.43 and a 52 week high of $131.88. The firm’s fifty day moving average is $125.80 and its 200-day moving average is $114.46. The firm has a market cap of $579.60 million, a P/E ratio of 15.59 and a beta of 0.44.

Invesco Pharmaceuticals ETF Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types.